Pharsight

Lonhala Magnair Kit patents expiration

LONHALA MAGNAIR KIT's oppositions filed in EPO

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6962151 SUMITOMO PHARMA AM Inhalation nebulizer
Oct, 2020

(3 years ago)

US7316067 SUMITOMO PHARMA AM Forming a perforate membrane by laser drilling and a subsequent electro-polishing step
Sep, 2022

(1 year, 9 months ago)

US8511581 SUMITOMO PHARMA AM Fluid droplet production apparatus and method
Nov, 2023

(7 months ago)

US7458372 SUMITOMO PHARMA AM Inhalation therapy device
Nov, 2024

(5 months from now)

US7931212 SUMITOMO PHARMA AM Fluid droplet production apparatus and method
Nov, 2025

(1 year, 5 months from now)

US11278683 SUMITOMO PHARMA AM Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Aug, 2026

(2 years from now)

US9265900 SUMITOMO PHARMA AM Disposable ampoule for an aerosol generating device
Dec, 2028

(4 years from now)

US10940110 SUMITOMO PHARMA AM Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations
Feb, 2029

(4 years from now)

US9789270 SUMITOMO PHARMA AM Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Oct, 2030

(6 years from now)

US9168556 SUMITOMO PHARMA AM Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Sep, 2032

(8 years from now)

US9604018 SUMITOMO PHARMA AM Aerosol therapy device
May, 2033

(8 years from now)

US10376661 SUMITOMO PHARMA AM Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Sep, 2035

(11 years from now)

US10688518 SUMITOMO PHARMA AM Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
Nov, 2036

(12 years from now)

US10744277 SUMITOMO PHARMA AM Aerosol delivery device and method of operating the aerosol delivery device
Dec, 2036

(12 years from now)

Lonhala Magnair Kit is owned by Sumitomo Pharma Am.

Lonhala Magnair Kit contains Glycopyrrolate.

Lonhala Magnair Kit has a total of 14 drug patents out of which 3 drug patents have expired.

Expired drug patents of Lonhala Magnair Kit are:

  • US6962151
  • US7316067
  • US8511581

Lonhala Magnair Kit was authorised for market use on 05 December, 2017.

Lonhala Magnair Kit is available in solution;inhalation dosage forms.

Lonhala Magnair Kit can be used as a method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd), long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

The generics of Lonhala Magnair Kit are possible to be released after 07 December, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date:

05 December, 2017

Treatment:

Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the ...

Dosage:

SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents